Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars

Coya and Dr Reddy’s enter exclusive worldwide agreement to develop COYA 302 (abatacept + COYA 301)

Mar 20, 2023

Coya Therapeutics, Inc. announced an exclusive worldwide licensing agreement with Dr Reddy’s Laboratories, Ltd for Coya to use the Dr Reddy’s abatacept biosimilar (to BMS’ Orenica®) to develop and commercialise its subcutaneous combination product COYA302 (abatacept with COYA 301), a dual biologic for neurodegenerative diseases.

COYA 301 is an investigational immunomodulatory cytokine for subcutaneous administration intended to enhance regulatory T cell (Treg) function in vivo, and Abatacept is a fusion protein that binds to antigen-presenting cells and downregulates T effector cells and other pro-inflammatory cells.

Coya retains exclusive rights to develop and commercialize COYA 302 across multiple neurodegenerative diseases in multiple territories, including North and South America, the EU, UK, and Japan.  Dr. Reddy’s obtains exclusive rights to commercialize COYA 302 elsewhere.

Coya expects to file an IND for COYA 302 in the second half of 2023 and intends to subsequently begin phase Ib/II trials for Amyotrophic Lateral Sclerosis.